NASDAQ:TVTX Travere Therapeutics (TVTX) Stock Price, News & Analysis → Massive Crisis Looming — Protect Your Savings Now (From Weiss Ratings) (Ad) Free TVTX Stock Alerts $7.33 +0.16 (+2.23%) (As of 04:20 PM ET) Add Compare Share Share Today's Range$7.03▼$7.4150-Day Range$5.26▼$7.8352-Week Range$5.12▼$17.73Volume957,293 shsAverage Volume1.21 million shsMarket Capitalization$558.03 millionP/E RatioN/ADividend YieldN/APrice Target$15.58 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Travere Therapeutics alerts: Email Address Travere Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.62 Rating ScoreUpside/Downside112.0% Upside$15.58 Price TargetShort InterestBearish17.69% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.15Based on 7 Articles This WeekInsider TradingSelling Shares$364 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.77) to ($1.64) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.05 out of 5 starsMedical Sector810th out of 913 stocksPharmaceutical Preparations Industry379th out of 429 stocks 3.3 Analyst's Opinion Consensus RatingTravere Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.62, and is based on 8 buy ratings, 5 hold ratings, and no sell ratings.Amount of Analyst CoverageTravere Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Travere Therapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted17.69% of the outstanding shares of Travere Therapeutics have been sold short.Short Interest Ratio / Days to CoverTravere Therapeutics has a short interest ratio ("days to cover") of 11.3, which indicates bearish sentiment.Change versus previous monthShort interest in Travere Therapeutics has recently increased by 0.22%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldTravere Therapeutics does not currently pay a dividend.Dividend GrowthTravere Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TVTX. Previous Next 3.4 News and Social Media Coverage News SentimentTravere Therapeutics has a news sentiment score of 1.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.92 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Travere Therapeutics this week, compared to 3 articles on an average week.Search Interest7 people have searched for TVTX on MarketBeat in the last 30 days. This is an increase of 17% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Travere Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $364.00 in company stock.Percentage Held by InsidersOnly 4.06% of the stock of Travere Therapeutics is held by insiders.Read more about Travere Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Travere Therapeutics are expected to grow in the coming year, from ($3.77) to ($1.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Travere Therapeutics is -3.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Travere Therapeutics is -3.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTravere Therapeutics has a P/B Ratio of 2.75. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Travere Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsAre you prepared for a financial lockdown?A new kind of American dystopia is being built before our eyes, and most people have no idea what's happening. That's why I've recorded this urgent message to give you all the details on how to prepare … Including three steps to take right now.Click here to watch my video before it's too late. About Travere Therapeutics Stock (NASDAQ:TVTX)Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.Read More TVTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TVTX Stock News HeadlinesJune 13, 2024 | americanbankingnews.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Receives Average Rating of "Moderate Buy" from AnalystsJune 11, 2024 | globenewswire.comTravere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 16, 2024 | markets.businessinsider.comBuy Rating on Travere Therapeutics: Filspari’s Market Potential and Positive Financial OutlookMay 15, 2024 | globenewswire.comTravere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 9, 2024 | globenewswire.comTravere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association CongressMay 8, 2024 | finance.yahoo.comLoss-Making Travere Therapeutics, Inc. (NASDAQ:TVTX) Expected To Breakeven In The Medium-TermMay 8, 2024 | sfgate.comGossamer Bio: Q1 Earnings SnapshotMay 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Travere Therapeutics on Strong Filspari Sales and Favorable Regulatory ProspectsMay 7, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Esperion (ESPR) and Travere Therapeutics (TVTX)May 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for Travere Therapeutics on Robust Drug Sales and Promising Market ExpansionMay 7, 2024 | markets.businessinsider.comBarclays Reaffirms Their Buy Rating on Travere Therapeutics (TVTX)May 7, 2024 | msn.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Q1 2024 Earnings Call TranscriptMay 7, 2024 | finance.yahoo.comTravere Therapeutics Inc (TVTX) Q1 2024 Earnings Call Transcript Highlights: Navigating Growth ...May 6, 2024 | finance.yahoo.comTravere Therapeutics Reports Q1 2024 Results: A Mixed Financial Performance Amidst Strategic ...May 6, 2024 | msn.comTVTX Stock Earnings: Travere Therapeutics Misses EPS, Misses Revenue for Q1 2024May 6, 2024 | finance.yahoo.comTravere Therapeutics Reports First Quarter 2024 Financial ResultsMay 6, 2024 | globenewswire.comTravere Therapeutics Reports First Quarter 2024 Financial ResultsMay 5, 2024 | msn.comTravere Therapeutics Q1 2024 Earnings PreviewApril 29, 2024 | globenewswire.comTravere Therapeutics to Report First Quarter 2024 Financial ResultsApril 26, 2024 | markets.businessinsider.comBuy Rating Affirmed for Travere Therapeutics Following Filspari’s European Approval and Promising US ProspectsApril 25, 2024 | markets.businessinsider.comBuy Rating Affirmed for Travere Therapeutics on EU Approval and Promising Revenue ProjectionsApril 24, 2024 | markets.businessinsider.comFILSPARI’s European Approval and Market Potential Bolster Buy Rating for Travere TherapeuticsApril 24, 2024 | globenewswire.comTravere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA NephropathyApril 24, 2024 | prnewswire.comCSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA NephropathyApril 14, 2024 | investing.comTravere Therapeutics CFO sells shares to cover tax obligationsSee More Headlines Receive TVTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Travere Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/06/2024Today6/17/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:TVTX CUSIPN/A CIK1438533 Webwww.retrophin.com Phone(888) 969-7879Fax302-645-1280Employees380Year FoundedN/APrice Target and Rating Average Stock Price Target$15.58 High Stock Price Target$27.00 Low Stock Price Target$9.00 Potential Upside/Downside+112.6%Consensus RatingModerate Buy Rating Score (0-4)2.62 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($2.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-111,400,000.00 Net Margins-87.94% Pretax Margin-226.71% Return on Equity-238.06% Return on Assets-52.87% Debt Debt-to-Equity Ratio5.10 Current Ratio2.78 Quick Ratio2.75 Sales & Book Value Annual Sales$145.24 million Price / Sales3.84 Cash FlowN/A Price / Cash FlowN/A Book Value$2.67 per share Price / Book2.75Miscellaneous Outstanding Shares76,130,000Free Float73,038,000Market Cap$558.03 million OptionableOptionable Beta0.77 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Eric M. Dube Ph.D. (Age 50)President, CEO & Director Comp: $1.4MMr. Christopher Cline C.F.A. (Age 39)Chief Financial Officer Comp: $709.94kMs. Elizabeth E. Reed J.D. (Age 53)Senior VP, General Counsel & Corporate Secretary Comp: $713.63kDr. William E. Rote Ph.D. (Age 61)Senior VP and Head of Research & Development Comp: $748.02kMr. Peter Heerma (Age 52)Chief Commercial Officer Comp: $742.37kMs. Sandra Calvin (Age 58)SVP, Corporate Controller & Chief Accounting Officer Ms. Naomi EichenbaumVice President of Investor RelationsMs. Charlotte SmithSenior Vice President of Public AffairsMs. Angela GiannantonioSenior Vice President of Human ResourcesMr. Casey LoganChief Business OfficerMore ExecutivesKey CompetitorsHarrowNASDAQ:HROWEpizymeNASDAQ:EPZMOmerosNASDAQ:OMERRigel PharmaceuticalsNASDAQ:RIGLJanux TherapeuticsNASDAQ:JANXView All CompetitorsInsiders & InstitutionsJacobs Levy Equity Management Inc.Sold 593,513 shares on 5/16/2024Ownership: 1.477%California State Teachers Retirement SystemSold 3,930 shares on 5/16/2024Ownership: 0.098%Bayesian Capital Management LPBought 22,935 shares on 5/16/2024Ownership: 0.030%Affinity Asset Advisors LLCBought 125,000 shares on 5/15/2024Ownership: 0.164%Price T Rowe Associates Inc. MDBought 2,948 shares on 5/15/2024Ownership: 0.041%View All Insider TransactionsView All Institutional Transactions TVTX Stock Analysis - Frequently Asked Questions Should I buy or sell Travere Therapeutics stock right now? 13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Travere Therapeutics in the last twelve months. There are currently 5 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" TVTX shares. View TVTX analyst ratings or view top-rated stocks. What is Travere Therapeutics' stock price target for 2024? 13 brokers have issued 1-year price objectives for Travere Therapeutics' stock. Their TVTX share price targets range from $9.00 to $27.00. On average, they predict the company's share price to reach $15.58 in the next twelve months. This suggests a possible upside of 112.0% from the stock's current price. View analysts price targets for TVTX or view top-rated stocks among Wall Street analysts. How have TVTX shares performed in 2024? Travere Therapeutics' stock was trading at $8.99 on January 1st, 2024. Since then, TVTX stock has decreased by 18.2% and is now trading at $7.35. View the best growth stocks for 2024 here. When is Travere Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our TVTX earnings forecast. How were Travere Therapeutics' earnings last quarter? Travere Therapeutics, Inc. (NASDAQ:TVTX) issued its quarterly earnings data on Monday, May, 6th. The company reported ($1.76) earnings per share for the quarter, missing the consensus estimate of ($0.98) by $0.78. The firm had revenue of $41.40 million for the quarter, compared to analysts' expectations of $43.46 million. Travere Therapeutics had a negative net margin of 87.94% and a negative trailing twelve-month return on equity of 238.06%. Travere Therapeutics's quarterly revenue was up 34.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.27) EPS. What ETF holds Travere Therapeutics' stock? Virtus LifeSci Biotech Products ETF holds 44,150 shares of TVTX stock, representing 1.67% of its portfolio. Who are Travere Therapeutics' major shareholders? Travere Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.23%), Jacobs Levy Equity Management Inc. (1.48%), Assenagon Asset Management S.A. (0.29%), Healthcare of Ontario Pension Plan Trust Fund (0.27%), Russell Investments Group Ltd. (0.24%) and Affinity Asset Advisors LLC (0.16%). Insiders that own company stock include Christopher R Cline, Elizabeth E Reed, Eric M Dube, Jula Inrig, Laura Clague, Noah L Rosenberg, Peter Heerma, Sandra Calvin, Steve Aselage and William E Rote. View institutional ownership trends. How do I buy shares of Travere Therapeutics? Shares of TVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TVTX) was last updated on 6/17/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredThis AI made her leave her jobThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredBill Clinton Backing Biden Replacement???Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be...The Freeport Society | SponsoredNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Weiss Ratings | SponsoredHe Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Travere Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.